TownSquare Capital’s Clearside Biomedical CLSD Stock Holding History

TownSquare Capital’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,333	Closed	-$123K	–	1109
2023 Q2	$123K	Buy	+7,333	New	+$126K	﹤0.01%	1017

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TownSquare Capital's CLSD Position: Q3 2023 in Review

TownSquare Capital sold out of Clearside Biomedical (CLSD) in Q3 2023, closing a stake of 7,333 shares — an estimated $123K sold.

TownSquare Capital first reported a position in CLSD in Q2 2023 and held it in 1 quarter. The position peaked at $123K in Q2 2023. 45 funds tracked by Wall St. Rank hold CLSD as of Q3 2023.

TownSquare Capital reported no remaining Clearside Biomedical position as of Q3 2023 after selling out during the quarter.
TownSquare Capital sold 7,333 Clearside Biomedical shares in Q3 2023, an estimated $123K.
TownSquare Capital first reported a position in Clearside Biomedical in Q2 2023 and held it in 1 quarter.
TownSquare Capital's Clearside Biomedical position peaked at $123K in Q2 2023.
45 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2023.

Based on TownSquare Capital's 13F filing for Q3 2023, filed 15 Nov 2023.